Lung Cancer

Articles

Data from The Lancet Oncology found that higher-dose radiotherapy of 60 Gy for patients with small cell lung cancer resulted in survival benefit while maintaining the toxicity profile compared with a radiotherapy at a dose of 45 Gy.

Higher-Dose Radiotherapy Improved Survival, Maintained Level of Toxicity for Limited-Stage SCLC

Original research published in the journal ONCOLOGY® explored the impacts of treatment refusal in patients with small cell lung cancer. 

Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung Cancer

Podcasts

The latest episode of the podcast dissects a piece of original research from the Journal ONCOLOGY focusing on the impact of treatment refusal on patients with small cell lung cancer.

Oncology Peer Review On-The-Go: Impact of Treatment Refusal on Survival for Small Cell Lung Cancer

Merck, the manufacturer of pembrolizumab, announced that it would be withdrawing the agent’s indication for the treatment of patients with previously treated SCLC.

Pembrolizumab’s Indication for the Treatment of SCLC in the US Is Withdrawn 

The approval of trilaciclib was based on results from a pooled analysis of intent-to-treat datasets from 3 studies of patients with extensive-stage small cell lung cancer in which patients received standard chemotherapy plus either trilaciclib or placebo.

FDA Approves Trilaciclib for Patients With SCLC Being Treated With Chemo

Racial and socioeconomic factors were associated with varying levels of survival for patients with limited-stage small cell lung cancer, with improved survival noted among African American and Asian patients compared with White patients.

Specific Racial, Socioeconomic Factors Associated with Improved Survival Rates for Patients with LS-SCLC

Liposomal irinotecan as second-line therapy for SCLC is feasible, safe after frontline platinum therapy failure.

After Platinum-Based Therapy, Liposomal Irinotecan Appears Effective, Safe for Second-Line SCLC

Updated data from a phase 2 trial of apatinib added to single-agent chemotherapy for small cell lung cancer in patients with prior treatments indicate a good efficacy and safety for the combination. 


Patients With Pretreated SCLC Have Improved Outcomes When Apatinib is Added to Chemo  

Data presented at the 2020 World Conference on Lung Cancer Singapore reported gains in survival at the population and patient levels for those with SCLC treated with immunotherapy.

Survival Gains Associated With Immuno-Oncology Found to be Significant for SCLC

Videos

The associate professor of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center indicated that these data provide the first avenue for personalized treatment of small cell lung cancer.

Small Cell Lung Cancer (SCLC) | Topics